Xilio Therapeutics, Inc. (NASDAQ:XLO) Short Interest Update

Xilio Therapeutics, Inc. (NASDAQ:XLO) was the recipient of a large drop in short interest during the month of May. As of May 31st, there was short interest totalling 791,500 shares, a drop of 35.1% from the May 15th total of 1,220,000 shares. Approximately 4.8% of the company’s shares are sold short. Based on an average daily volume of 1,240,000 shares, the days-to-cover ratio is currently 0.6 days.

Xilio Therapeutics Price Performance

NASDAQ XLO opened at $0.66 on Monday. The company has a market cap of $34.30 million, a P/E ratio of -0.39 and a beta of -0.01. The stock has a 50-day moving average of $0.78 and a two-hundred day moving average of $0.88. Xilio Therapeutics has a 1-year low of $0.62 and a 1-year high of $1.70.

Xilio Therapeutics (NASDAQ:XLO) last announced its quarterly earnings data on Tuesday, May 13th. The company reported ($0.18) earnings per share for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.28). The company had revenue of $2.93 million for the quarter, compared to analysts’ expectations of $42.00 million. On average, analysts anticipate that Xilio Therapeutics will post -1.14 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. Geode Capital Management LLC grew its holdings in shares of Xilio Therapeutics by 6.0% in the fourth quarter. Geode Capital Management LLC now owns 358,422 shares of the company’s stock valued at $342,000 after purchasing an additional 20,230 shares in the last quarter. Renaissance Technologies LLC grew its holdings in shares of Xilio Therapeutics by 11.4% in the fourth quarter. Renaissance Technologies LLC now owns 296,617 shares of the company’s stock valued at $283,000 after purchasing an additional 30,317 shares in the last quarter. ADAR1 Capital Management LLC acquired a new position in shares of Xilio Therapeutics in the first quarter valued at approximately $29,000. Aptus Capital Advisors LLC acquired a new position in shares of Xilio Therapeutics in the fourth quarter valued at approximately $39,000. Finally, Raymond James Financial Inc. acquired a new position in shares of Xilio Therapeutics in the fourth quarter valued at approximately $48,000. Institutional investors and hedge funds own 54.29% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Wall Street Zen raised Xilio Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, May 22nd.

Xilio Therapeutics Company Profile

Xilio Therapeutics, Inc, a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company’s checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors.